The SBV515 Dye from Bio-Rad improves brightness to enhance its use in flow cytometry.
The StarBright Violet 515 (SBV515) Dye, a range of fluorescent nanoparticles from Bio-Rad Laboratories, can enhance flow cytometry. With an excitation maximum at 401 nanometers and emission maximum of 516 nanometers, the dye improves brightness to solve rare and low antigen density populations. In addition, its narrow emission profile reduces spillover onto other filters and allows only minimal excitation by other lasers.
The dye is not vulnerable to photobleaching, distributes high lot-to-lot reproducibility, and is stable at 4° C with no loss of signal. There is also no requirement to use a special staining buffer, which allows for integration into common experimental protocols without compromising performance.
“StarBright Violet 515 Dye is brighter than other common dyes that emit at similar wavelengths,” said Mike Blundell, Bio-Rad product manager, Life Science Group, in a Sept. 14, 2020 press release. “The dye is flexible enough to fit into any flow cytometry panel, allowing researchers to multiplex with ease regardless of flow cytometer and experimental protocol, and it offers a superior alternative for fluorophores that have emission maxima between 500 and 550 nanometers.”
Source: Bio-Rad
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.